Treatment of adjustment disorder stemming from romantic betrayal using memory reactivation under propranolol: A open-label interrupted time series trial

J Affect Disord. 2022 Nov 15:317:98-106. doi: 10.1016/j.jad.2022.08.082. Epub 2022 Aug 27.

Abstract

Objectives: In a sustained relationship, romantic betrayal is a catastrophic event that can precipitate an adjustment disorder (AD). Surprisingly, there exists no empirically validated treatment for AD, despite its high prevalence in clinical practice. Considering the promise of memory reactivation under propranolol (i.e., reconsolidation interference) for treating posttraumatic stress disorder, we sought to extend this finding to AD, given that in both disorders, symptoms stem from an identified stressor.

Method: A single-blind interrupted time series design was used to examine the efficacy of memory reactivation under propranolol to alleviate symptoms of AD. After being placed on a 4-week waitlist, sixty-one participants received 5 weekly 25-min treatments during which they recalled the betrayal event, 1 h after having orally ingested the beta-blocker propranolol.

Results: Segmented regression analyses on the intent-to-treat sample revealed that AD symptoms significantly decreased during the treatment phase (pre/post Cohen's d = 1.44), compared to the waitlist phase (d = 0.01). Significant pre/post reductions in anxio-depressive symptomatology were also found. Improvement was maintained at the 4-month follow-up on all outcomes.

Conclusion: Memory reactivation under propranolol shows promise in reducing symptoms of AD. This study provides the theoretical framework and necessary effect sizes to inform larger, double-blind, placebo-controlled clinical trials.

Trial registration: ClinicalTrials.gov NCT03151681.

Keywords: Propranolol; Reconsolidation; Romantic attachment; Stress; Therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjustment Disorders
  • Adrenergic beta-Antagonists / therapeutic use
  • Betrayal*
  • Humans
  • Interrupted Time Series Analysis
  • Propranolol* / therapeutic use
  • Single-Blind Method

Substances

  • Adrenergic beta-Antagonists
  • Propranolol

Associated data

  • ClinicalTrials.gov/NCT03151681